Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled study of CUV1647 implants in erythropoietic protoporphyria
2007-000636-13Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Feb 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of Afamelanotide in erythropoietic protoporphyria (EPP) (2 arms), sponsored by Clinuvel Pharmaceuticals. Started Feb 2008; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on 2007-000636-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000636-13.